Relmada Therapeutics Stock Forecast
NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 12:53 PM ET
RLMD analyst consensus
Consensus (4 analysts)
none
Avg. price target
$10.75+239.12%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Relmada Therapeutics (2026-10-08), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $10.75, with a high estimate of $12.00 and a low estimate of $9.00. The average target implies upside of 239.1% from the current price of $3.17.
The spread between the highest and lowest targets is 33.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RLMD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 25% |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | +183.91% |
| Average target | $10.75 | +239.12% |
| High target | $12.00 | +278.55% |